furosemide has been researched along with Fibrosis in 13 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effects of both the prolonged-release (PR) formulation of torasemide (torasemide-PR) and furosemide on myocardial fibrosis in hypertensive patients with chronic HF." | 9.15 | Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. ( , 2011) |
| "Loop diuretics, such as torasemide and furosemide, are important agents in the treatment of chronic heart failure." | 9.14 | TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. ( Anguita, M; Castro-Beiras, A; Cobo, E; Coca, A; Conthe, P; de Teresa, E; Díez, J; Fernández, E, 2009) |
| "Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis." | 7.85 | Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017) |
| "In human cirrhosis, adrenergic hyperfunction causes proximal tubular fluid retention and contributes to diuretic-resistant ascites, and clonidine, a sympatholytic drug, improves natriuresis in difficult-to-treat ascites." | 7.83 | Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine. ( Aragno, M; Mastrocola, R; Mengozzi, G; Parola, M; Sansoè, G, 2016) |
| "The aim of this study was to evaluate the effects of both the prolonged-release (PR) formulation of torasemide (torasemide-PR) and furosemide on myocardial fibrosis in hypertensive patients with chronic HF." | 5.15 | Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. ( , 2011) |
| "Loop diuretics, such as torasemide and furosemide, are important agents in the treatment of chronic heart failure." | 5.14 | TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. ( Anguita, M; Castro-Beiras, A; Cobo, E; Coca, A; Conthe, P; de Teresa, E; Díez, J; Fernández, E, 2009) |
| "Our previous study indicates that hydrochlorothiazide inhibits transforming growth factor (TGF)-β/Smad signaling pathway, improves cardiac function and reduces fibrosis." | 3.85 | Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. ( Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z, 2017) |
| "In human cirrhosis, adrenergic hyperfunction causes proximal tubular fluid retention and contributes to diuretic-resistant ascites, and clonidine, a sympatholytic drug, improves natriuresis in difficult-to-treat ascites." | 3.83 | Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine. ( Aragno, M; Mastrocola, R; Mengozzi, G; Parola, M; Sansoè, G, 2016) |
| "Spironolactone treatment demonstrated significant attenuation of cardiac fibrosis and apoptosis in left ventricular tissue compared to furosemide." | 1.72 | Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction. ( Chang, WT; Chen, CY; Chen, ZC; Lin, YW; Liu, PY; Luo, CY; Shih, JY; Wu, CC, 2022) |
| "In 23 patients with cirrhotic ascites, the daily administered initial dosage of 100 mg of spironolactone was increased by 100 mg/day at intervals of 5 days until either diuresis commenced or TTKG fell below 3." | 1.31 | Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites. ( Han, JS; Kim, CY; Kim, KA; Lee, HS; Lim, YS; Yoon, JH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Nakatsukasa, T | 1 |
| Ishizu, T | 1 |
| Ouchi, M | 1 |
| Murakoshi, N | 1 |
| Sato, K | 1 |
| Yamamoto, M | 1 |
| Kawanishi, K | 1 |
| Seo, Y | 1 |
| Ieda, M | 1 |
| Chang, WT | 1 |
| Lin, YW | 1 |
| Chen, CY | 1 |
| Chen, ZC | 1 |
| Shih, JY | 1 |
| Wu, CC | 1 |
| Luo, CY | 1 |
| Liu, PY | 1 |
| Rivero, J | 1 |
| Rodríguez, F | 1 |
| Soto, V | 1 |
| Macedo, E | 1 |
| Chawla, LS | 1 |
| Mehta, RL | 1 |
| Vaingankar, S | 1 |
| Garimella, PS | 1 |
| Garza, C | 1 |
| Madero, M | 1 |
| Kolkhof, P | 1 |
| Pook, E | 1 |
| Pavkovic, M | 1 |
| Kretschmer, A | 1 |
| Buchmüller, A | 1 |
| Tinel, H | 1 |
| Delbeck, M | 1 |
| Mondritzki, T | 1 |
| Wasnaire, P | 1 |
| Dinh, W | 1 |
| Truebel, H | 1 |
| Hüser, J | 1 |
| Schmeck, C | 1 |
| Yamazaki, T | 1 |
| Nakamura, Y | 1 |
| Shiota, M | 1 |
| Osada-Oka, M | 1 |
| Fujiki, H | 1 |
| Hanatani, A | 1 |
| Shimada, K | 1 |
| Miura, K | 1 |
| Yoshiyama, M | 1 |
| Iwao, H | 1 |
| Izumi, Y | 1 |
| Buggey, J | 1 |
| Mentz, RJ | 1 |
| Pitt, B | 1 |
| Eisenstein, EL | 1 |
| Anstrom, KJ | 1 |
| Velazquez, EJ | 1 |
| O'Connor, CM | 1 |
| Sansoè, G | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Mengozzi, G | 1 |
| Parola, M | 1 |
| Luo, J | 1 |
| Chen, X | 1 |
| Luo, C | 1 |
| Lu, G | 1 |
| Peng, L | 1 |
| Gao, X | 1 |
| Zuo, Z | 1 |
| Díez, J | 2 |
| Coca, A | 1 |
| de Teresa, E | 1 |
| Anguita, M | 1 |
| Castro-Beiras, A | 1 |
| Conthe, P | 1 |
| Cobo, E | 1 |
| Fernández, E | 1 |
| Lim, YS | 1 |
| Han, JS | 1 |
| Kim, KA | 1 |
| Yoon, JH | 1 |
| Kim, CY | 1 |
| Lee, HS | 1 |
| López, B | 1 |
| González, A | 1 |
| Beaumont, J | 1 |
| Querejeta, R | 1 |
| Larman, M | 1 |
| Cowley, AW | 1 |
| Roman, RJ | 1 |
| Kaldunski, ML | 1 |
| Dumas, P | 1 |
| Dickhout, JG | 1 |
| Greene, AS | 1 |
| Jacob, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Furosemide Stress Test as a Predictor of Tubular Atrophy and Interstitial Fibrosis in Patients With Chronic Kidney Disease[NCT02417883] | Phase 3 | 100 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
| Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure[NCT00409942] | Phase 4 | 142 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [NCT00005268] | 0 participants | Observational | 1995-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for furosemide and Fibrosis
| Article | Year |
|---|---|
A reappraisal of loop diuretic choice in heart failure patients.
Topics: Choice Behavior; Fibrosis; Furosemide; Heart; Heart Failure; Humans; Myocardium; Practice Patterns, | 2015 |
3 trials available for furosemide and Fibrosis
| Article | Year |
|---|---|
TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure.
Topics: Chronic Disease; Collagen Type I; Delayed-Action Preparations; Diuretics; Female; Fibrosis; Furosemi | 2009 |
Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study.
Topics: Aged; Biomarkers; Chronic Disease; Delayed-Action Preparations; Diuretics; Endpoint Determination; F | 2011 |
Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure.
Topics: Adult; Aged; Antihypertensive Agents; Blotting, Western; Endocardium; Extracellular Matrix; Female; | 2007 |
9 other studies available for furosemide and Fibrosis
| Article | Year |
|---|---|
Sodium Glucose Co-Transporter 2 Inhibitors Improve Renal Congestion and Left Ventricular Fibrosis in Rats With Hypertensive Heart Failure.
Topics: Animals; Canagliflozin; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hypertension; Kidney; | 2022 |
Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction.
Topics: Animals; Fibrosis; Furosemide; Heart Failure; Mineralocorticoid Receptor Antagonists; Mitral Valve I | 2022 |
Furosemide stress test and interstitial fibrosis in kidney biopsies in chronic kidney disease.
Topics: Adult; Biopsy; Disease Progression; Female; Fibrosis; Furosemide; Humans; Kidney; Kidney Tubules, Pr | 2020 |
Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aorta; Arterial Pressure; CHO Cells; Cricetulus; | 2019 |
Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
Topics: Acute-Phase Reaction; Animals; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibr | 2013 |
Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine.
Topics: Adrenergic Agonists; Animals; Ascites; Canrenoic Acid; Clonidine; Diuretics; Drug Synergism; Fibrosi | 2016 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2017 |
Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites.
Topics: Diuretics; Drug Therapy, Combination; Female; Fibrosis; Furosemide; Humans; Kidney Tubules; Male; Mi | 2002 |
Brown Norway chromosome 13 confers protection from high salt to consomic Dahl S rat.
Topics: Angiotensin II; Animals; Blood Pressure; Fibrosis; Furosemide; Gene Transfer Techniques; Genetic The | 2001 |